Irish journal of medical science · 2025
The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozturk Huseyin Ali, Sumbul Hilmi Erdem
Аннотация
AIM: Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure.
METHODS: In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).
RESULTS: NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).
CONCLUSION: Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.
METHODS: In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).
RESULTS: NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).
CONCLUSION: Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.